US FDA Advisers Back Onyx Pharmaceuticals Blood Cancer Drug-Reuters

Reuters reported that U.S. drug advisers backed Onyx Pharmaceuticals’s drug for patients who have failed to successfully treat their blood cancer with other medicines, making it likely the drug would secure approval from U.S. regulators. A panel of outside advisers to the Food and Drug Administration voted unanimously to recommend approval of Onyx’s drug, to be sold as Kyprolis, for treating multiple myeloma in people who have tried at least two other medicines.